Drug Profile
Latanoprost - Altacor
Alternative Names: Latanoprost-CDLatest Information Update: 21 Jan 2022
Price :
$50
*
At a glance
- Originator OphthalmoPharma
- Developer Altacor
- Class Antiglaucomas; Prostaglandins; Small molecules
- Mechanism of Action Prostaglandin F2 alpha agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Glaucoma
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for clinical-Phase-Unknown development in Glaucoma in England (Ophthalmic)
- 04 Aug 2015 Altacor has been acquired by Esperante Ventures
- 27 Jul 2011 Clinical trials in Glaucoma in England (Ophthalmic)